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1. The lack of construct validity of pre-clinical models used in drug screening, the irreversibility of 
changes introduced by signalling dysfunction and the absence of early diagnostic tools explain 
the differential pharmacological effects of analgesic drugs in animals and humans. This thesis
2. Poor experimental design can lead to inaccuracies in parameter estimation and consequently to 
biased selection and ranking. This thesis
3. The characterization of exposure-response relationships is a conditio sine qua non for the dose 
rationale of analgesic drugs, regardless whether they are aimed at symptomatic pain relief, 
disease modification or prophylaxis. This thesis
4. In contrast to the maximum tolerated dose and other empirical approaches in Phase 1 and 2 
trials, the use of biomarkers offers a basis for the personalization of therapy from the very start 
of clinical development. This thesis
5. The intrinsic refractoriness to treatment with analgesic drugs reflects disease heterogeneity, 
irrespective of the exposure levels. This thesis
6. The reasons for discontinuation of a drug discovery program are neither well investigated 
nor published, leading to speculative and unsubstantiated claims. Whiteside et al. 
Neuropharmacology, 54:767-775, 2008
7. Since the accurate characterization of PKPD relationships is not a formal requirement for the 
regulatory approval of new analgesic drugs, the evidence generated may be uninformative or 
even biased. (EMEA guideline on Clinical Medicinal Products for the Treatment of Nociceptive 
Pain, London, 2002)
8. Treatment of neuropathic pain is often poorly understood by healthcare professionals and 
consequently not managed well. The selection of tricyclic antidepressants and anticonvulsants 
as the drugs of choice, in terms of effectiveness, can therefore be compared to using cannons to 
shoot a duck. (Allen, CEACCP 5: 134-137, 2005)
9. The most commonly used numeric rating scales for pain screening have only modest accuracy 
for identifying patients with clinically important pain and are consequently inadequate for the 
quantitative assessment of efficacy. (Krebs et al., J Gen Intern Med. 22: 1453–1458, 2007)
10. The yardstick for evaluating a good scientist are the number of publications and successful 
grants. It’s rarely good science.(Author’s view).
11. Everything should be made as simple as possible, but not simpler. (Einstein)
12. I have often heard ABDs (all but dissertation) remark, ‘If only I could finish my thesis, my troubles 
would be over’. (David Sternberg, How to complete and survive a doctoral dissertation. New York, 
1981)
13. In today’s digital era the printing of hard copies of a thesis only contributes to increasing our 
carbon footprint, and is thus an outdated practice. (Author’s view)
Amit Taneja, 20th November 2013
